Lupus NephritisPhase 4SYNERGYNCT07225387
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
A Phase 4 study testing Voclosporin in people with Lupus Nephritis, run by NephroNet, Inc. at 7 sites in United States.
Trial summary
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lupus Nephritis
- What is being tested?
- Voclosporin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 7 sitesUnited States
- Study dates
- 1 Oct 2024to Jan 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed Informed Consent Form
- Age 18-80 years at time of signing Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- A diagnosis of SLE by any one of the following criteria: European League Against Rheumatism/ American College of Rheumatology/Systemic Lupus International Collaborating Clinics (EULAR/ACR/SLICC)
- At least one positive ANA defined as a >1:80 titer or a positive anti-ds-DNA within the last 3 years will be accepted.
- ISN/RPS 2003 Class III, Class IV, Class III/V or Class IV/V Lupus Nephritis diagnosed and meet one of these criteria:
Show all 36Show fewer
- A new diagnosis of LN (kidney biopsy current by SOC), or ii) A previous diagnosis of LN that has been treated, responded, but has flared (If diagnostic biopsy was >24 months before SCREENING, a SOC repeat biopsy will be required for trial entry or by Medical Monitor approval if the last biopsy was less than 36 months prior to screening), or iii) A current diagnosis of LN confirmed by SOC kidney biopsy within the last 24 months prior to screening, or by Medical Monitor approval if the last biopsy - was less than 36 months prior to screening, who has been treated with MMF + glucocorticoids
- UPCR must be >750 mg/gm from a 24 hour urine collection during screening. If the UPCR does not exceed 750 mg/gm, it may be repeated once during the screening period.
- Resting systolic blood pressure <150 mm Hg and resting diastolic blood pressure <90 mm Hg.
- Note: If the blood pressure is >150/90 at screening it can be repeated twice in the screening period and if it is <150/90 upon repeat the subject is eligible for study enrollment.
- Subject must be on maximum tolerated ACEi or ARB therapy as adjudicated by the site PI for ≥4 weeks prior to randomization.
- Note: Patients with confirmed ACEi or ARB intolerance defined as persistent cough, anaphylaxis, or angioedema will be eligible and treatment with another protein-lowering anti-hypertensive encouraged (See #9).
- Use of other protein-lowering agents, including non-dihydropyridine calcium channel blockers, sodium-glucose transporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRA), will be allowed provided dosing has been stable for ≥4 weeks prior to randomization.
- Note: Titration of the above antihypertensive agents will NOT be allowed following randomization without Sponsor approval. Control for changes in blood pressure will be accomplished using non-protein lowering agents (e.g. Amlodipine, Nifedipine, or Hydralazine).
- EGFR >30 ml/min/1,73m2 will be required for kidney biopsies obtained >3.0 months from the start of drug administration.
- EGFR> 20 mls/min/1.73 m2 will be allowed for renal biopsies obtained <3.0 months from start of study drug administration provided interstitial fibrosis/tubular atrophy and/or global glomerulosclerosis <65%, and in the judgement of the PI the decrease in eGFR is due to ATN that is reversible.
- Note: All patients will interstitial fibrosis/tubular atrophy and/or global glomerulosclerosis >65% will be excluded from the trial Note: If a patient underwent a renal biopsy within 6 months of randomization and found to have a eGFR between 20-30 ml/min/1,73m2, the site will consult with the study Medical Monitor(s) to determine eligibility.
- Note: The rationale for this is to allow patient to that have low eGFR with intense and active inflammation.
- Eligible patients will have adequate hematologic parameters defined below as:
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
- Absolute lymphocyte count (ALC) ≥ 1.0 x 109/L. Note: If count is between .5 x 109/L and 1.0 x 109/L , the site will consult with the study Medical Monitor(s) to determine eligibility.
- Platelet count > 75 x 109/L
- Hemoglobin > 8.5 g/dL
- Subjects must be taking Belimumab prior to Consent / Screening or start on Day 0 / Baseline (randomization to short-term MMF or MPA therapy or extended MMF or MPA therapy).
- Note: If Belimumab therapy is expected for less than 12 months in duration post-randomization, please contact Sponsor for approval on a case-by-case basis.
- Subjects of Child-Bearing Potential must use a highly effective method of contraception consistently and correctly during the study.
- Highly effective methods of contraception have a failure rate of <1% per year when used consistently and correctly.
- The following methods of contraception are considered highly effective:
- Combined hormonal (estrogen+progestin) contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation.
- Progestogen- or progestin-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation.
- Intrauterine device.
- Intrauterine hormone-releasing system.
- Bilateral tubal ligation/occlusion/division.
- Vasectomized partner (considered a highly effective birth control method provided that partner is the sole sexual partner of the study subject and that the vasectomized partner has received medical assessment of the surgical success).
- Sexual abstinence: defined as refraining from intercourse which may result in pregnancy during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the subject.
- Note: Subjects who are on oral contraceptive must also use additional barrier contraceptive methods, consistent with the approved prescribing information for MMF and MPA.
Who cannot join
- 1. Currently on renal replacement therapy (dialysis or a kidney transplant), has had dialysis within 3 months of screening or is expected to require renal replacement therapy within 6 months of screening 2. Received cyclophosphamide within 12 weeks of study drug administration 3. Has received treatment with any of the following prior to screening:
- Rituximab or Obinutuzumab within 24 weeks of screening and there is no measure of circulating C19 B cells. If the measure of circulating C19 B cells is over 10%, the subject will be eligible for study participation.
- Use of Atacicept, BION-1301, Sibeprenlimab, Povetacicept, or other agents, with the exception of Belimumab, that directly inhibit B call activating factor (BAFF) and/or a proliferation inducing ligand (APRIL) within 12 weeks of study screening.
- 4. Use of High dose Human Immunoglobulin therapy, abatacept, adalimumab, infliximab, certolizumab, etanercept, golimumab, anakinra, canakinumab, tocilizumab, sarilumab, Satralizumab, Ustekinumab, and Anifrolumab within 12 weeks of study screening.
- 5. Pure Class V LN on biopsy. 6. In the opinion of the Investigator, subject does not require long-term immunosuppressive treatment (in addition to corticosteroids).
- 7. Any known hypersensitivity or contraindication to MMF, MPA, Cyclosporine, Tacrolimus, Voclosporin Corticosteroids, Belimumab or any components of these drug products.
Show all 16Show fewer
- 8. Current or medical history of:
- Pancreatitis or gastrointestinal hemorrhage within 6 months prior to screening.
- Active unhealed peptic ulcer within 3 months prior to screening. If an ulcer has healed and the subject is on adequate therapy, the subject may be randomized. 9. Positive human immunodeficiency virus (HIV) infection. 10. In the opinion of the Investigator, clinically significant drug or alcohol abuse 2 years prior to screening.
- 11. Known malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas of the skin Note: Subjects with cervical dysplasia that is CIN1, but have been treated with conization or LEEP, and have had a normal repeat PAP are allowed.
- 12: Lymphoproliferative disease or previous total lymphoid irradiation. 13. Known viral infection (such as HBV and HCV) within 3 months of screening. If HBC and HCV status is unknown, testing should be performed during screening. Subjects with past medical history of HBC or HCV exposure with positive antibodies may be enrolled if a DNA PCR test was negative.
- 14. Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid. QuantiFERON gold test must be negative at screening or subject taking isoniazid. Note: If positive at screening the subject can be screen failed, treated, and rescreened in 4 weeks with a confirmed negative chest x-ray.
- 15. Patients with known "poor intravenous access" WILL be allowed to participate having placement of a "passport",or port, central IV access or its equivalent for subjects requiring IV infusions of Belimumab upon review and approval by the Medical Monitor 16. Other known clinically significant active medical conditions, such as:
- Severe cardiovascular disease, including congestive heart failure b) history of cardiac dysrhythmia or congenital long QT syndrome. QTcF (QT interval duration corrected for heart rate using method of Fridericia) exceeding 480 msec in the presence of a normal QRS interval (<110 msec) on historic ECG, if available. An ECG is not is not required for study entry.
- 17. Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or bilirubin greater than 2.5 times the upper limit of normal) at screening.
- -
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Piedmont Physicians Rheumatology
Atlanta, Georgia, 30318
Kimberly Pruitt, 404-367-3350, kimberly.pruitt@piedmont.org
Wambui Machua, MD
- Recruiting
Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center
Columbus, Ohio, 43201
Laci Roberts, 614-685-5323, laci.roberts@osumc.edu
Isabelle Ayoub, MD
- Recruiting
AARA Clinical Research
Fort Worth, Texas, 76109
Lainne Carey, 214-276-6560 ext. 627, Lainne.Carey@aaracr.com
Shariq Chudhri, DO
- Recruiting
AARA Clinical Research
Glendale, Arizona, 85306
Cody Price, 602-386-4970 ext. 320, Garth.Price@aaracr.com
Eric Peters, MD
- Recruiting
Georgia Nephrology Research Institute
Lawrenceville, Georgia, 30046
Jeremy Whitson, CCRA, CCRP, 423-943-4264, jwhitson@ganephrology.com
Terry Smith, 423-967-0917, tsmith@nephronet.com
- Recruiting
Parris & Associates
Lawrenceville, Georgia, 30046
Mannai Coutermarsh, 678-471-6289, m.coutermarsh@parrisandassociates.net
Glen Parris, MD
- Recruiting
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
Kallena Haynes, 405-271-3046, Kallena-haynes@omrf.org
Christina Arriens, MD
About this study
Official title: Safety and EfficacY of CombinatioN Belimumab and Voclosporin in the TrEatment of PRoliferative Forms of Lupus Glomerulopathy: Synergy Trial
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
Read the detailed description
Lupus nephritis (LN) is the most serious common manifestation of systemic lupus erythematosus (SLE) and will ultimately affect about half of patients with SLE. LN increases the morbidity and mortality of patients with SLE, especially if Chronic Kidney Disease (CKD) and end-stage kidney disease (ESKD) develop. Morbidity and mortality are significantly mitigated if treatment-induced complete remission (CR) is achieved. While partial remission (PR) is better than no remission, its impact on renal survival is much less than CR. Within the last two years VCS and BEL have been approved for the treatment of LN, bescause each drug was shown to increase the number of patients having CR in well-conducted phase III trials. However, the overall proportion of patients achieving CR was below 50% in each trial, leaving a large unmet need for most patients with LN. Because VCS and BEL target different effector arms of the immune system relevant to kidney injury in LN, and individually have excellent safety profiles, investigators postulated that for the treatment of LN the combination of VCS and BEL with a significant reduction in mycophenolate-based immunosuppression may be complementary and safe, and would ultimately increase the proportion of patients who achieve a CR. In addition, both drugs offer different kidney-protective effects that favor long-term preservation of kidney function. Specifically, VCS protects podocytes and BEL reduces the LN flare rate and through unknown mechanisms, attenuates the decline in GFR seen in LN patients. Investigators further postulate that the combination of these targeted treatments will significantly reduce the need for non-specific immunosuppressives (cytotoxic agents and antimetabolites).
- Conditions
- Lupus Nephritis
- Being tested
- Voclosporin
- Keywords
- Lupus Nephritis, Voclosporin, Belimumab, MMF, MPA, Prednisone, Proteinura, SYNERGY
- Medical subject headings
- Lupus Nephritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VoclosporinDrug
The trial is an open label, parallel, randomized study with patients randomized 1:1 the EARLY MMF TERMINATION (90 days) ARM or the EXTENDED MMF (360 days) ARM looking at the addition of Voclosporin in patients with Lupus Nephritis taking Belimumab, MMF, and Prednisone.
| Study group | Role | What they receive |
|---|---|---|
| EARLY MMF TERMINATION (90 days) ARM | Active comparator | EARLY MMF TERMINATION (90 days) ARM in which subjects are randomized 1:1 Receives: Drug: Voclosporin |
| EXTENDED MMF (360 days) ARM | Active comparator | EXTENDED MMF TERMINATION (360 days) ARM in which subjects are randomized 1:1 Receives: Drug: Voclosporin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome Measure: Day 360 (12 Month) Outcome
Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 12 months.
CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not >20% below baseline, no rescue meds, sustained on repeat assessment 30 days later.
Measured: 12 months
Secondary outcomes (4)
Secondary Outcome Measure #1: Day 180 (6 Month) Outcome
Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 6 months.
CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not >20% below baseline, no rescue meds.
Measured: 6 months
Secondary Outcome Measure-#2:
Proportion of Patients achieving and maintaining a Partial Clinical Renal Remission (PCRR) at 6 and 12 months.
PCRR is defined as: A UPCR from a SPOT or 24-hour urine collection ≤50% of UPCR at baseline and eGFR not >20% below baseline eGFR sustained on repeat measurement at Day 180 (6 months) and Day 360 (12 months).
Measured: 6 and 12 months
Secondary Outcome Measure-#3:
Effectiveness of combination therapy on successful discontinuance of MMF. Examine the proportion of patients achieving CCRR who discontinued MMF after 90 days and compare to the proportion of patients achieving CCRR who continued MMF for the 360 Day (12 month) duration of the trial. Expectation is no difference in efficacy.
Measured: 12 months
Secondary Outcome Measure-#4:
The proportion of patients requiring rescue therapy. Rescue therapy defined as: A patient requiring an increase in glucocorticoid (prednisone) to 1 mg/kg/d or intravenous solumedrol >80 mg for over a week, or the addition of, or change to cyclophosphamide, eculizumab, rituximab, therapeutic plasmapheresis, or an experimental therapeutic.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2025
- Study start1 Oct 2024
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lupus NephritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The trial has 2 interventional arms. One treatment regimen is provided to study subjects.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NephroNet, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- James Tumlin, MD, Principal investigator, NephroNet, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07225387
- Sponsor's protocol ID
- NephroNet-24-009
- Acronym
- SYNERGY
- Status last verified
- Nov 2025
- First submitted
- 26 Sep 2025
- Last updated
- 6 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and EfficacY of CombinatioN Belimumab and Voclosporin in the TrEatment of PRoliferative Forms of Lupus Glomerulopathy: Synergy Trial
- ClinicalTrials.gov ID
- NCT07225387
- Acronym / sponsor ID
- SYNERGY / NephroNet-24-009
- Conditions
- Lupus Nephritis
- Keywords
- Lupus Nephritis, Voclosporin, Belimumab, MMF, MPA, Prednisone, Proteinura, SYNERGY
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- NephroNet, Inc.University, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 6 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
Detailed description
Lupus nephritis (LN) is the most serious common manifestation of systemic lupus erythematosus (SLE) and will ultimately affect about half of patients with SLE. LN increases the morbidity and mortality of patients with SLE, especially if Chronic Kidney Disease (CKD) and end-stage kidney disease (ESKD) develop. Morbidity and mortality are significantly mitigated if treatment-induced complete remission (CR) is achieved. While partial remission (PR) is better than no remission, its impact on renal survival is much less than CR. Within the last two years VCS and BEL have been approved for the treatment of LN, bescause each drug was shown to increase the number of patients having CR in well-conducted phase III trials. However, the overall proportion of patients achieving CR was below 50% in each trial, leaving a large unmet need for most patients with LN. Because VCS and BEL target different effector arms of the immune system relevant to kidney injury in LN, and individually have excellent safety profiles, investigators postulated that for the treatment of LN the combination of VCS and BEL with a significant reduction in mycophenolate-based immunosuppression may be complementary and safe, and would ultimately increase the proportion of patients who achieve a CR. In addition, both drugs offer different kidney-protective effects that favor long-term preservation of kidney function. Specifically, VCS protects podocytes and BEL reduces the LN flare rate and through unknown mechanisms, attenuates the decline in GFR seen in LN patients. Investigators further postulate that the combination of these targeted treatments will significantly reduce the need for non-specific immunosuppressives (cytotoxic agents and antimetabolites).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The trial has 2 interventional arms. One treatment regimen is provided to study subjects.
| Arm | Type | Receives |
|---|---|---|
| EARLY MMF TERMINATION (90 days) ARM | Active comparator | Drug: VoclosporinEARLY MMF TERMINATION (90 days) ARM in which subjects are randomized 1:1 |
| EXTENDED MMF (360 days) ARM | Active comparator | Drug: VoclosporinEXTENDED MMF TERMINATION (360 days) ARM in which subjects are randomized 1:1 |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (36 listed)
- Signed Informed Consent Form
- Age 18-80 years at time of signing Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- A diagnosis of SLE by any one of the following criteria: European League Against Rheumatism/ American College of Rheumatology/Systemic Lupus International Collaborating Clinics (EULAR/ACR/SLICC)
- ISN/RPS 2003 Class III, Class IV, Class III/V or Class IV/V Lupus Nephritis diagnosed and meet one of these criteria:
Key exclusion criteria (16 listed)
- 1. Currently on renal replacement therapy (dialysis or a kidney transplant), has had dialysis within 3 months of screening or is expected to require renal replacement therapy within 6 months of screening 2. Received cyclophosphamide within 12 weeks of study drug administration 3. Has received treatment with any of the following prior to screening:
- Rituximab or Obinutuzumab within 24 weeks of screening and there is no measure of circulating C19 B cells. If the measure of circulating C19 B cells is over 10%, the subject will be eligible for study participation.
- Use of Atacicept, BION-1301, Sibeprenlimab, Povetacicept, or other agents, with the exception of Belimumab, that directly inhibit B call activating factor (BAFF) and/or a proliferation inducing ligand (APRIL) within 12 weeks of study screening.
- 4. Use of High dose Human Immunoglobulin therapy, abatacept, adalimumab, infliximab, certolizumab, etanercept, golimumab, anakinra, canakinumab, tocilizumab, sarilumab, Satralizumab, Ustekinumab, and Anifrolumab within 12 weeks of study screening.
- 5. Pure Class V LN on biopsy. 6. In the opinion of the Investigator, subject does not require long-term immunosuppressive treatment (in addition to corticosteroids).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VoclosporinThe trial is an open label, parallel, randomized study with patients randomized 1:1 the EARLY MMF TERMINATION (90 days) ARM or the EXTENDED MMF (360 days) ARM looking at the addition of Voclosporin in patients with Lupus Nephritis taking Belimumab, MMF, and Prednisone. | Drug | EARLY MMF TERMINATION (90 days) ARM, EXTENDED MMF (360 days) ARM |
Primary outcome
Primary Outcome Measure: Day 360 (12 Month) Outcome
Time frame: 12 months
Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 12 months. CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not >20% below baseline, no rescue meds, sustained on repeat assessment 30 days later.
4 secondary outcomes
Secondary Outcome Measure #1: Day 180 (6 Month) Outcome
Time frame: 6 months
Secondary Outcome Measure-#2:
Time frame: 6 and 12 months
Secondary Outcome Measure-#3:
Time frame: 12 months
Secondary Outcome Measure-#4:
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2025.
Related trials for Lupus Nephritis
RecruitingPhase 4
Dapagliflozin in Active Lupus Nephritis
Lupus Nephritis (LN)
RecruitingPhase 1
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lupus Erythematosus, Systemic
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
James Tumlin, MD principal investigator
NephroNet, Inc.
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Voclosporin in people with Lupus Nephritis, run by NephroNet, Inc. at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 36 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jeremy Whitson (423-943-4265, jwhitson@nephronet.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome Measure: Day 360 (12 Month) Outcome (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2025.